Instrument Inactif

Communiqués Zogenix, Inc. Nasdaq

Actions

US98978L1052

Produits pharmaceutiques

Communiqués

27/06/22	UCB updates financial guidance for 2022 while maintaining 2025 financial guidance	AQ
07/03/22	UCB Completes Acquisition of Zogenix, Inc.	PR
07/03/22	ZOGENIX, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
07/03/22	Zogenix To Present New Long-term Data on FINTEPLA (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022	AQ
07/03/22	Zogenix : Amendment to Annual Report (Form 10-K/A)	PU
04/03/22	Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022	AQ
01/03/22	ZOGENIX, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION (form 10-K)	AQ
28/02/22	Zogenix : Provides Corporate Update and Reports Fourth Quarterand Full-Year 2021 Financial Results - Form 8-K	PU
28/02/22	Zogenix: Q4 Earnings Snapshot	AQ
28/02/22	Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results	AQ
24/02/22	ZOGENIX, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
15/02/22	Zogenix Supports New No-Cost Genetic Testing Program with United Mitochondrial Disease Foundation to Improve Diagnosis of Mitochondrial Diseases	AQ
19/01/22	Zogenix : UCB to acquire Zogenix - Form 8-K	PU
19/01/22	ZOGENIX, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
19/01/22	UCB to acquire Zogenix	PR
21/12/21	Zogenix Submits New Drug Application for FINTEPLA® (Fenfluramine) in Japan for the Treatment of Epileptic Seizures Associated with Dravet Syndrome	AQ
21/12/21	Zogenix Submits Type II Variation Application to the European Medicines Agency (EMA) to Expand the Use of FINTEPLA (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome	AQ
20/12/21	Zogenix Submits Type II Variation Application to the European Medicines Agency (EMA) to Expand the Use of FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome	AQ
16/12/21	Zogenix Reports Granting of Inducement Awards	GL
02/12/21	Zogenix To Present New FINTEPLA® (fenfluramine) Data at AES 2021	GL
02/12/21	Zogenix To Present New FINTEPLA® (fenfluramine) Data at AES 2021	GL
02/12/21	Zogenix Announces U.S. FDA Acceptance for Priority Review of Supplemental New Drug Application for FINTEPLA (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)	AQ
02/12/21	ZOGENIX, INC. : Other Events (form 8-K)	AQ
01/12/21	Zogenix Announces U.S. FDA Acceptance for Priority Review of Supplemental New Drug Application for FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)	AQ
17/11/21	Zogenix Reports Granting of Inducement Awards	GL